[1]李翔,李喜香△,刘军刚.中西药联用治疗糖尿病前期疗效和安全性的Meta分析[J].西部中医药,2020,33(01):72.[doi:10.12174/j.issn.1004-6852.2020.01.20]
　LI Xiang,LI Xixiang,LIU Jungang.Meta Analysis of Curative Effects of Integrative Medicine in the Treatment for Prediabetes and Its Safety[J].Western Journal of Traditional Chinese Medicine,2020,33(01):72.[doi:10.12174/j.issn.1004-6852.2020.01.20]
点击复制

中西药联用治疗糖尿病前期疗效和安全性的Meta分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年01期
页码:
72
栏目:
出版日期:
2020-01-15

文章信息/Info

Title:
Meta Analysis of Curative Effects of Integrative Medicine in the Treatment for Prediabetes and Its Safety
文章编号:
1004-6852(2020)01-0072-07
作者:
李翔1，李喜香2△，刘军刚2
1 甘肃中医药大学药学院，甘肃 兰州 730000； 2 甘肃省中医院药学部
Author(s):
LI Xiang1, LI Xixiang2△, LIU Jungang2
1 Pharmacy College, Gansu University of Chinese Medicine, Lanzhou 730000, China; 2 Pharmacy Department, Gansu Provincial Hospital of Traditional Chinese Medicine
关键词:
糖尿病前期; 系统评价; 中西药联用; Meta分析
Keywords:
prediabetes;  systematic evaluation;  integrative medicine;  Meta analysis
分类号:
R587
DOI:
10.12174/j.issn.1004-6852.2020.01.20
文献标志码:
A
摘要:
目的：评价中西药联合干预治疗糖尿病前期的疗效和安全性。方法：检索中国期刊全文数据库(CNKI)、万方数据库、VIP、CBM、Cochrane图书馆、Embase、PubMed、web of science、swetswise linker，检索时限截至2019年6月。纳入中西药联合干预治疗糖尿病前期的随机对照实验(RCT)。由2位研究人员根据纳入与排除标准，独立进行文献筛选、数据提取、质量评价、并交叉核对结果，采用RevMan5.3软件进行Meta分析。结果：共纳入19个RCT，共1584例糖尿病前期患者。Meta分析显示中西联合用药组与对照组比较，有效率升高［RR=1.25，95%CI(1.17，1.33)，P＜0.000 01］，对HbA1c[WMD=0.40，95%CI(0.25，0.56)，P＜0.000 01]、FPG[WMD=0.53，95%CI(0.41，0.66)，P＜0.000 01]、2hPG[WMD=0.62，95%CI(0.50，0.74)，P＜0.000 01]、TG[WMD=0.26，95%CI(0.07，0.45)，P=0.007]的影响其差异有统计学意义；对HOMA-IR[WMD=0.19，95%CI(-0.10，0.47)，P=0.20]、TC[WMD=0.32，95%CI(-0.07，0.70)，P=0.11]、FINS[WMD=0.18，95%CI(-0.07，0.44)，P=0.16]的影响其差异无统计学意义。19篇被纳入的文献中，仅有10篇文献提及不良反应，其中有4个研究报导了不良反应发生率，中西药联用组不良反应发生率低于对照组，差异均有统计学意义(P＜0.05)；其余9篇文献未提及安全性和不良反应，所有文献均未见严重的不良反应报道。结论：基于当前临床证据初步得出，中西药联合干预治疗糖尿病前期的方法可能优于单纯西药治疗。但纳入文章研究设计质量不高，可能存在发表偏倚，因此本研究结果仍需大样本多中心随机对照试验进一步验证。
Abstract:
Objective: To assess curative effects and the safety of integrative medicine in the intervention for prediabetes. Methods: Randomized controlled trials(RCTs) of integrative medicine in the treatment for prediabetes were searched in CNKI, Wanfang, VIP, CBM, Cochrane library, Embase, PubMed, web of science and swetswise linker by June, 2019. According to the inclusion and exclusion criteria, the papers were screened, the data was abstracted, quality was assessed and the results were checked by two researchers independently, RevMan 5.3 software was used to perform Meta analysis. Results: All 19 RCTs were included, involving 1 584 patients. Meta analysis demonstrated: integrative medicine group was compared with the control group, effective rate rose [RR=1.25, 95%CI(1.17, 1.33), P＜0.000 01], the difference showed statistical meaning in its effects on HbA1 [WMD=0.40, 95%CI(0.25, 0.56), P＜0.000 01], FPG[WMD=0.53, 95%CI(0.41 , 0.66), P＜0.000 01], 2hPG[WMD=0.62, 95%CI(0.50, 0.74), P＜0.00 001] and TG[WMD=0.26, 95%CI(0.07, 0.45), P=0.007]; the difference had no statistical meaning in its effects on HOMA-IR[WMD=0.19, 95%CI(-0.10, 0.47), P=0.20], TC[WMD=0.32, 95%CI(-0.07, 0.70), P=0.11] and FINS[WMD=0.18, 95%CI(-0.07, 0.44), P=0.16]. Among 19 papers, only ten papers refered to side effects, among them, four studies have reported the incidence of side effects, integrative medicine group was lower than the control group notably, and the difference had statistical meaning(P＜0.05); the rest nine papers haven't mentioned the safety and side effects, no severe side effects have been reported in all the papers. Conclusion: Based on the current clinical evidence, the method of integrative medicine in treating prediabetes might be superior to only Western medicine. Because the quality of experimental design in the included paper is low, publication bias might existed, the result needs to be testified in large-sample multicentered randomzied controlled trials.

相似文献/References:

[1]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(01):77.
[2]王晓怀,寇嘉宁,潘文,等.黄芪注射液治疗脑梗死的Meta分析[J].西部中医药,2014,27(10):67.
[3]王延玲,指导：裴建.耳穴贴压干预糖尿病前期糖代谢水平的临床观察[J].西部中医药,2014,27(11):4.
[4]闫乾,陈锋△,黄有荣,等.活血化瘀中药制剂治疗脊髓型颈椎病有效性和安全性的系统评价*[J].西部中医药,2015,28(02):53.
[5]王舒雅,欧光顺,陈虹△,等.小儿智力糖浆对比利他林治疗儿童注意缺陷多动障碍疗效和安全性的系统评价[J].西部中医药,2015,28(02):67.
[6]魏春秀.老年股骨粗隆间骨折内固定术后康复护理疗效的系统评价[J].西部中医药,2015,28(04):69.
[7]赖乾,智方圆,袁振洁.单纯针刺与药物治疗周围性面瘫疗效的系统评价[J].西部中医药,2015,28(07):59.
[8]王晓怀,潘文,康开彪,等.黄芪注射液治疗不稳定型心绞痛的系统评价[J].西部中医药,2013,26(10):61.
　WANG Xiaohuai,PAN Wen,KANG Kaibiao,et al.Systematic Review on HuangQi Injection in Treating Unstable Angina Pectoris[J].Western Journal of Traditional Chinese Medicine,2013,26(01):61.
[9]文惠方,任芳,徐厚谦,等.中药灌肠和口服2种给药途径治疗慢性盆腔炎的文献评价[J].西部中医药,2014,27(02):76.
　WEN Huifang,REN Fang,XU Houqian,et al.Systemic Review of Treatment for Chronic Pelvic Inflammatory Disease by TCM Enema and Oral Administration of TCM[J].Western Journal of Traditional Chinese Medicine,2014,27(01):76.
[10]张军红,许影,拜争刚,等.整体护理对老年抑郁症患者临床疗效影响的系统评价[J].西部中医药,2016,29(07):72.
　ZHANG Junhong,XU Ying,BAI Zhenggang,et al.Systematic Evaluation of Holistic Nursing on Clinical Effects of the Elderly Patients with Depression[J].Western Journal of Traditional Chinese Medicine,2016,29(01):72.

备注/Memo

备注/Memo:
收稿日期：2018-07-15*基金项目：甘肃省中医药综合防治重大疑难疾病项目(GZKZD-2018-01)。作者简介：李翔(1994—)，女，在读硕士研究生。研究方向：中药制药工艺。△通讯作者：李喜香(1968—)，女，硕士学位，硕士研究生导师，主任中药师。研究方向：中药新制剂研发。
更新日期/Last Update: 2020-01-15